Abbvie 4Q Revenues: $15.1 billion (+2%) 4Q Earnings: $2.5 billion (-39%) FY Revenues: $58.1 billion (+3%) FY Earnings: $11.8 billion (+3%) Comments: Global revenues from the immunology portfolio were $7.9 billion in the quarter, up 18%. Humira sales were $5.6 billion, up 5%. U.S. Humira sales were $5.0 billion, an increase of 10% percent, while international sales were $573 million, down 27% due to biosimilar competition. Skyrizi sales were $1.6 billion, up 76%. Rinvoq sales were $770 milli...